BT2 Suppresses Human Monocytic-Endothelial Cell Adhesion, Bone Erosion and Inflammation.
Mei-Chun YehBen J WuYue LiMina ElahyLeonel Prado-LourencoJim SocklerHerman LauRichard Osborne DayLevon Michael KhachigianPublished in: Journal of inflammation research (2021)
BT2 is a novel small molecule inhibitor of joint inflammation, bone erosion, pro-inflammatory cytokine and adhesion molecule expression. This suggests the potential clinical utility of BT2 as a new anti-inflammatory agent.
Keyphrases
- cell adhesion
- small molecule
- endothelial cells
- oxidative stress
- bone mineral density
- anti inflammatory
- poor prognosis
- bone loss
- soft tissue
- bone regeneration
- signaling pathway
- induced pluripotent stem cells
- postmenopausal women
- pluripotent stem cells
- human health
- cystic fibrosis
- risk assessment
- biofilm formation
- pseudomonas aeruginosa
- cell migration